IE930184L - 4-demethoxy-4-amino-anthracyclines - Google Patents

4-demethoxy-4-amino-anthracyclines

Info

Publication number
IE930184L
IE930184L IE930184A IE930184A IE930184L IE 930184 L IE930184 L IE 930184L IE 930184 A IE930184 A IE 930184A IE 930184 A IE930184 A IE 930184A IE 930184 L IE930184 L IE 930184L
Authority
IE
Ireland
Prior art keywords
demethoxy
daunomycinone
amino
formula
deoxy
Prior art date
Application number
IE930184A
Other versions
IE80627B1 (en
Inventor
Michele Caruso
Antonino Suarato
Francesco Angelucci
Federico Arcamone
Original Assignee
Vincent Michael Mcnamara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878709353A external-priority patent/GB8709353D0/en
Priority claimed from GB888803302A external-priority patent/GB8803302D0/en
Application filed by Vincent Michael Mcnamara filed Critical Vincent Michael Mcnamara
Priority to IE930184A priority Critical patent/IE80627B1/en
Priority claimed from IE117188A external-priority patent/IE63510B1/en
Publication of IE930184L publication Critical patent/IE930184L/en
Publication of IE80627B1 publication Critical patent/IE80627B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Description

4-DEMETHOXY-4-AMINO-ANTHRACYCLINES The invention relates to a process for preparing intermediates for use in the preparation of anthracycline glycosides.
The intermediates may be used to prepare e.g. anthracycline glycosides having the general formula (I): wherein Rx represents a hydrogen atom or a hydroxyl group, one of Ra and R~ represents a hydrogen atom and the other of R2 and r3 represents a hydrogen atom or a hydroxyl group, and their pharmaceutically acceptable addition salts.
B 0 o 2 7 The glycosides of formula (I) and their pharmaceutically acceptable addition salts are prepared by a process in which the starting material is a daunomycinone derivative of formula (II): 21 wherein the 4-amino group is protected. This process is described in Irish application no: 1171/88 from which the present application is divided.
The daunomycinone derivative of formula (II) and protected derivatives thereof wherein the 4-amino group is protected . may be prepared by a process which comprises: 5 (a) removing by hydrogenolysis the 7a-hydroxyl group of carminomycinone of formula (V): H 6H (b) reacting the resultant 4-demethyl-7-deoxy-daunomycinone of formula (VI): VI with 4-fluorobenzensulfonyl chloride in the presence of N,N-diisopropylethylamine and a catalytic amount of 4-dimethylaminopyridine; (c) reacting the resultant 4-demethoxy-4-0-5 I4-fluorobenzensulfonyl]-7-deoxy-daunomycinone of formula (VII): VII with benzylamine; (d) removing the benzyl group from the resultant 4-demethoxy-4-benzylamino-7-deoxy-daunomycinone of formula (VIII): VIII by catalytic hydrogenation; (e) protecting the 4-amino group of the resultant 4-demethoxy-4-amino-7-deoxy-daunomycinone of formula (IX): (f) reintroducing the 7a-hydroxy group into the resultant compound of formula (X): - G - wherein X' represents the amino protecting group, thereby obtaining a protected derivative of formula (XI) of a daunomycinone derivative of formula (II): XI wherein X' is defined above; and (g) if desired, removing the 4-amino protecting group from the protected derivative of formula (XI), thereby obtaining the daunomycinone derivative of formula (II): II This process is illustrated in Scheme I below. The starting compound for the process is the natural carminomycinone (V). The sulfonylation reaction, step (b), leads only the substituted C-4-O-sulfonyl derivative (VII), 5 leaving the C-6-0H and C-11-0H unaffected. It should be stressed that this unexpected selectivity has been achieved only under the conditions described herein.
Reaction (c) is a new one in anthracycline chemistry, probably due to the withdrawing effect both of 10 the guinone moiety and of the 4-fluoro-benzensulfonyl group at the position C-4. Preferably, the reaction is effected in tetrahydrofuran at room temperature. Step (e) is preferably effected with trifluoroacetic anhydride. Preferably, therefore Xr represents a trifluoroacetyl group 15 in formulae (X) and (XI). Step (f) may be performed according to the method described by £.M. Hong et al., Can.J.Chem., 51, 446 (1973). Preferably, it is effected by protecting the 13-keto group of a 4-demethoxy-4-(protected - 8 -Scheme I (a) H 6h VI (c) (d) (f) IX XII COCF jNH A 6H XIII (g) amino)-7-deoxy-daunomycinone compound of formula (XII): XII by treatment with ethylene glycol; brominating the resultant compound at the 7-position; and hydrolysing the 7-bromo and 13-ketal groups to give 4-demethoxy-4-N-tri-fluoroacetamido-daunomycinone of formula (XIII): XIII Bromination is generally achieved by treatment with bromine or N-bromosuccinimide in the presence of 2,2'-azo-bis(iso-butyronitrile).
The intermediates of formula (II) and (IX) are also useful for the preparation of 4-demethoxy-7-deoxy-daunomycinone or 4-demethoxy-daunomycinone. 4-Demethoxy-7-deoxy-daunomycinone can be converted into 4-demethoxy-daunomycinone. Further antitumor anthracycline glycosides can be prepared from 4-demethoxy-daunomycinone.
According to the present invention, there therefore is provided a suitable process for preparing 4-demethoxy-7-deoxy-daunomycinone or 4-demethoxy-daunomycinone of formula (XIV): XIV in which R4 represents hydrogen or hydroxy, which process comprises diazotising the 4-amino group of 4-demethoxy-4-amino-7-deoxy-daunomycinone or 4-demethoxy-4-amino-daunomycinone of formula (XV): XV in which R4 is as defined above, and reducing under mild conditions the diazonium compound thus-formed.
Anthracyclinones bearing an amino group at position C-4 are therefore transformed into their corresponding desamino derivatives. The starting compounds are 4-demethoxy-4-amino-7-deoxy-daunomycinone (IX(XVa, R - H)) and 4-demethoxy-4-amino-daunomycinone (IX (XVb, R-OH)). The removal of the 4-amino group, via diazotisation and mild reduction, leads to the well known 4-demethoxy-7-deoxy-daunomycinone (XlVa, R«H) or 4-demethoxy-daunomycinone (XlVb, R-OH). As shown in Scheme II, diazotisation is preferably effected using aqueous sodium nitrite. The mild reduction is preferably effected using hypophosphorous acid.
Scheme II 1) aq H&H02 2) Hypophocphor acid Compound XVa in which R4-H can be easily transformed into compound XVb in which R4»OH by standard methods. Preferably, the 4-demethoxy-4-amino-7-deoxy-daunomycinone (XVa) or 4-demethoxy-4-amino-daunomycinone (XVb), dissolved in aqueous 37% hydrochloric acid, is reacted at a temperature of from 0° to 5°C and for 1 hour with an aqueous solution of sodium nitrite and, subsequently, for 5 hours at room temperature under vigorous stirring with an aqueous solution of 50% hypophosphorous acid, the reaction mixture is extracted with methylene dichloride and the solvent is removed under reduced pressure. converted into 4-demethoxy-daunomycinone (XlVb) by introducing a hydroxy group at the 7-position. This can be achieved according to the invention by bromination of the 7-position, for example by bromine or N-bromo-succinimide (NBS), followed by treatment with 4-Demethoxy-7-deoxy-daunomycinone (XlVa) may be alkali or with silver acetate or methanolysis of the acetate thus formed. 4-Demethoxy-daunomycinone (XlVb) is the aglycone moiety of the useful antitumor drug 4-demethoxy- daunorubicin (XVI). Accordingly, the present invention further provides a process for preparing 4-demethoxy-daunorubicin of formula (XVI): or a pharmaceutically acceptable salt thereof; which process comprises reacting 4-demethoxy-daunomycinone, which is represented by formula (XIV) in which R4 is hydroxy and which has been prepared from 4-demethoxy-4-amino-daunomycinone by a process according to the invention, with an appropriate sugar derivative and, if desired, converting the 4-demethoxy-daunorubicin thus-obtained into a pharmaceutically acceptable salt thereof.
The sugar derivative may have the formula (XVII): Hal wherein Bal represents a halogen atom, R4 represents a protected hydroxy group and R7 represents a protected amino group. The protecting groups are removed after reaction with 4-demethoxy-daunomycinone. Preferably Hal is a chlorine atom. The hydroxy group may be protected by a trifluoroacetyl group. The amino group may be protected by a trifluoroacetyl group also. - 15 Example 1 Preparation of 4-demethoxv-7-deoxy-daunomycinone (XlVa) 1.78 g (5 mmol) of 4-demethoxy-4-amino-7-deoxy-daunomycinone (IX) dissolved with 75 ml of aqueous 37% hydrochloric acid, are cooled at 0-5°C and 75 ml of an aqueous solution containing 0.6 g of sodium nitrite is added. The mixture is stirred for one hour at 0-5°C. Then 75 ml of an aqueous solution of 50% hypophosphorous acid is added and the mixture is kept at room temperature for five hours under vigorous stirring.
The solution is diluted with 200 ml of water and extracted with methylene dichloride. The organic layer is separated off, dried over anhydrous sodium sulphate and the solvent is removed under reduced pressure to give a quantitative yield (1.7 g) of 4-demethoxy-7-deoxy- 1 daunomycinone (XlVa), analytically compared with a standard i sample.
Example 2 preparation of 4-demethoxy-daunomycinone (XlVb) 1.86 g (5 mmol) of 4-demethoxy-4-amino-daunomycinone (II) 1 are transformed into the corresponding 4-demethoxy-daunomycinone (XlVb) following the method above described. Yield: 1.8 g of compound XlVb analytically compared with a standard sample.

Claims (4)

- 17 -CLAIMS
1. A process for preparing 4-demethoxy-7- deoxy daunomycinone or 4-demethoxy-daunomycinone of formula XIV XIV in which R4 is hydrogen or hydroxy which process comprises diazotising the 4-amino group of 4-demethoxy-4-amino-7-daunomycinone or 4-demethoxy-4-amino-daunomycinone of formula XV 0 OH 10 I ^ L JL^JL J yja XV in which R4 is defined above, and reducing under mild conditions the diazonium compound thus-formed.
2. A process according to claim 1 in which the diazotisation comprises treating the compound of formula XV 15 with an aqueous solution of sodium nitrite.
3. A process according to claim 1 or 2 in which the reduction is carried out by reaction using hypophosphorus acid. - 18 -
4. A process according to any one of claims 1 to 3 substantially as described herein with reference to the Examples. TOMKINS & CO.
IE930184A 1987-04-21 1988-04-19 4-Demethoxy-4-Amino-Anthracyclines IE80627B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IE930184A IE80627B1 (en) 1987-04-21 1988-04-19 4-Demethoxy-4-Amino-Anthracyclines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB878709353A GB8709353D0 (en) 1987-04-21 1987-04-21 4-demethoxy-4-amino-anthracyclines
GB888803302A GB8803302D0 (en) 1988-02-12 1988-02-12 Conversion of 4-demethoxy-4-amino anthracyclinones into 4-demethoxy-anthracyclinones
IE117188A IE63510B1 (en) 1987-04-21 1988-04-19 4-Demethoxy-4- amino-anthracyclines
IE930184A IE80627B1 (en) 1987-04-21 1988-04-19 4-Demethoxy-4-Amino-Anthracyclines

Publications (2)

Publication Number Publication Date
IE930184L true IE930184L (en) 1988-10-21
IE80627B1 IE80627B1 (en) 1998-10-21

Family

ID=27263393

Family Applications (1)

Application Number Title Priority Date Filing Date
IE930184A IE80627B1 (en) 1987-04-21 1988-04-19 4-Demethoxy-4-Amino-Anthracyclines

Country Status (1)

Country Link
IE (1) IE80627B1 (en)

Also Published As

Publication number Publication date
IE80627B1 (en) 1998-10-21

Similar Documents

Publication Publication Date Title
EP0426653B1 (en) 4-demethoxy-4-amino-anthracyclines
US4345070A (en) Process for the preparation of 4'-deoxy-daunorubicin and 4'-deoxy-doxorubicin
EP0051280B1 (en) Anthracycline glycosides, process for the preparation thereof, intermediate compounds and their preparation and pharmaceutical compositions
EP0254484B1 (en) 6-amino anthracyclines, process for their preparation and use thereof
JP2516769B2 (en) New anthracyclines
EP0199920B1 (en) New antitumor anthracyclines
EP0381989B1 (en) New 4'-epi-4'-amino anthracyclines
IE930184L (en) 4-demethoxy-4-amino-anthracyclines
AU632102B2 (en) New 3'-(4-morpholinyl)- and 3'-(2-methoxy-4-morpholinyl)- anthracycline derivatives
EP0475071B1 (en) 2-acyloxy-4-morpholinyl anthracycline
WO1990001490A1 (en) 4-substituted anthracyclinones and anthracycline glycosides and their preparation
JPH0778073B2 (en) Nitroanthracycline, process for its production and use thereof
US5412081A (en) New 4'-epi-4'-amino anthracyclines
CA1131218A (en) Process for the preparation of new antitumor glycosides
KR950013771B1 (en) Method for preparing 14-chlorodaunomycin and method for preparing (2 "R) -4'-O-tetrahydropyranyl adriamycin
GB2034707A (en) Anthracycline glycosides
SI8910940A8 (en) Process for obtaining 4-demethoxy-antracyclinones
IL104975A (en) 4-Demethoxydoxorubicin- and daunomycin-4- carboxylic acids, esters thereof, their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
MM4A Patent lapsed